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Abstract: A nanoparticle delivery system termed dynamic magnetic shift (DMS) has the 
potential to more effectively treat metastatic cancer by equilibrating therapeutic magnetic 
nanoparticles throughout tumors. To evaluate the feasibility of DMS, histological liver sections 
from autopsy cases of women who died from breast neoplasms were studied to measure vessel 
number, size, and spatial distribution in both metastatic tumors and normal tissue. Consistent 
with prior studies, normal tissue had a higher vascular density with a vessel-to-nuclei ratio of 
0.48 ± 0.14 (n = 1000), whereas tumor tissue had a ratio of 0.13 ± 0.07 (n = 1000). For tumors, 
distances from cells to their nearest blood vessel were larger (average 43.8 µm, maximum 
287 µm, n ≈ 5500) than normal cells (average 5.3 µm, maximum 67.8 µm, n ≈ 5500), implying 
that systemically delivered nanoparticles diffusing from vessels into surrounding tissue would 
preferentially dose healthy instead of cancerous cells. Numerical simulations of magnetically 
driven particle transport based on the autopsy data indicate that DMS would correct the problem 
by increasing nanoparticle levels in hypovascular regions of metastases to that of normal tissue, 
elevating the time-averaged concentration delivered to the tumor for magnetic actuation versus 
diffusion alone by 1.86-fold, and increasing the maximum concentration over time by 1.89-fold. 
Thus, DMS may prove useful in facilitating therapeutic nanoparticles to reach poorly vascular-
ized regions of metastatic tumors that are not accessed by diffusion alone.
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Introduction
Breast cancer is the second leading cause of death in American women.1 The most 
important factor that determines survival in these patients is tumor stage, but more 
specifically the presence of metastases. The 5-year relative survival rate declines 
from 98% in cases with localized primary lesions to 23% in cases with distant stage 
with metastasis in organs.1 Treatment of breast cancer includes local strategies such 
as surgery and radiation, as well as the systemic use of chemotherapeutic agents. 
However, successful treatment of metastases is a daunting undertaking due to the 
numerous challenges involved.2 Identification of efficacious antitumor agents, tumor 
heterogeneity, evolving drug resistance, and host toxicity are among the difficulties 
involved in developing therapies that reduce morbidity and mortality in patients with 
advanced disease.
The three-dimensional tumor microenvironment introduces an additional level 
of complexity, as the rapid and uncontrolled growth of tumor cells can result in a 
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disorganized and only partially functional biological milieu, 
an environment that favors tumor growth over normal 
physiological processes. One outcome of this process is 
an abnormal vascular system.3 Unlike the well-structured 
series of small vessels that create a fine meshwork of cap-
illaries in normal tissues to deliver oxygen and nutrients 
within a diffusion-limited distance of cells, tumors often 
exhibit a complex and disordered blood supply, resulting 
in diminished perfusion to some or all parts of the tumor 
microenvironment and reduced delivery of blood-borne 
components, including systemically administered thera-
peutic agents.4–9
The full complement of reasons for poor chemothera-
peutic efficacy in metastases is not understood;4,6 however, 
to improve drug delivery, functionalized nanoparticles are 
being developed to target cancers and increase local drug 
concentrations, cellular uptake, and clinical effectiveness.10–18 
Unlike small drug molecules that equilibrate quickly through 
tissue space by diffusion alone,19,20 larger functionalized 
nanoparticles (including targeting antibodies,10–12,14,15 
  environmental reactive drugs,21 or imaging reagents22,23) are 
unable to diffuse as easily.19,20 Several in vivo studies have 
shown that with targeted carriers, even if the cellular uptake is 
increased, the tumor drug concentration remains unchanged 
compared with untargeted carriers.11–13 This poor penetra-
tion can reduce the efficacy of large nanoparticle carriers, 
particularly within poorly vascularized cellular regions in 
the tumor environment.
In order to provide adequate nanoparticle concentrations 
to breast and other metastatic tumors, we are evaluating a 
new method of normalizing nanotherapy30–37 (see Figure 1) 
that is designed to achieve two important goals: (1) increase 
nanoparticle levels in poorly vascularized tumors or tumor 
subregions by equalizing the concentration between tumor 
and normal tissues, and (2) improve tumor nanoparticle levels 
simultaneously in all tumor foci across a given anatomical 
region, without the need for imaging-based, positional infor-
mation of lesions. To accomplish these objectives, magnetic 
nanoparticles would be given systemically and allowed to 
distribute throughout the body. A magnetic force would then 
be applied in one direction over a specified anatomical zone 
of the body to promote movement of the therapeutic particles 
into the tumor space from adjacent, well-vascularized normal 
tissue (an effective external nanoparticle reservoir) and also 
from subregions within the tumor that contain high levels of 
nanoparticles (eg, internal vessels). The externally applied 
magnetic forces would overcome diffusion limits by physi-
cally displacing ferromagnetic drug carriers across nano- or 
micrometer distances (Figure 2). This displacement can be 
driven in one direction only, but our studies show that it is 
advantageous to repeat the process in at least two directions 
to more uniformly distribute the nanoparticles due to the 
complex geometries of vessels within tumor foci. Because 
the nanoparticles have a finite circulation time in vivo, there 
is a balance between magnetically actuating for as long 
as possible in one direction versus successively applying 
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Figure 1 A map of when dynamic magnetic shift (DMS) is predicted to be advantageous over diffusion alone for poorly perfused liver metastases (for a sample 0.5 mm 
diameter tumor, therapeutic particles are assumed to have a 45-minute in vivo residence time). For two common types of tissue models, a Renkin Pore model19,20,24 or a 
Fiber-Matrix model,19,20,25 the coloring shows when DMS treatment will improve drug delivery to the tumor. Here, “High diffusion” refers to the region where diffusion alone 
should suffice. It is the region where particle diffusion is predicted to create a concentration of therapy in all tumor cells that is $85% of the concentration of therapy in the 
bloodstream. “Some advantage” (yellow) and “Most advantageous” (red) is where diffusion will not suffice and DMS has the potential to improve therapy concentration to 
all cells in the tumor by .17% and .100%, respectively, compared with diffusion alone. Thus, DMS will be advantageous for mid-range 10–500 nm particle sizes, when the 
particles are big enough that diffusion alone is no longer effective but small enough that they can be magnetically moved through tissue. Particles of this size include heat shock 
protein cages (,16 nm),26 polymeric micelles (,50 nm),27 colloidal suspensions of albumin-Taxol (Abraxane, 130 nm),28 and functionalized carbon nanotubes (0.1–4 µm).29
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magnetic forces in multiple directions to better redistribute 
drugs into and throughout metastatic tumors. Our finding is 
that two directions is a practical compromise between shift 
distance and number of shift directions, and we examine 
that case here.
To evaluate the histological and vascular features of 
metastatic foci in human subjects and their implications for 
magnetic drug delivery, a series of autopsy cases from women 
who died from metastatic breast cancer were   analyzed. 
Blood vessel density and geographic distribution were quan-
titatively measured and these data used for mathematical 
simulations of the distribution of magnetic particles within 
tumors with and without magnetic actuation, to assess the 
feasibility of dynamic magnetic shift (DMS) and also to 
describe and understand the critical elements that affect the 
process. In brief, strong magnets of a carefully selected size 
(20 × 40 cm) that create substantial magnetic gradients inside 
the body (magnetic fields fall off with distance creating a spa-
tial gradient) were evaluated; the magnetic fields, gradients, 
and forces were computed by standard methods;32,38–41 the 
most realistic available parameters were used for human tis-
sue resistance to particle motion;19,20,24 and DMS parameters 
(strength and timing for a two-direction shift) were varied to 
evaluate different treatment regimens. Finally, because one 
of the most common sites for metastasis of breast cancer is 
the liver and there is clinical evidence suggesting that treat-
ment of metastatic hepatic lesions can lead to improvement 
in patient outcome, we focused our attention on hepatic 
metastasis.2,42–44
Materials and methods
Evaluation of autopsy reports  
and specimen selection
Autopsy reports of patients with metastatic breast cancer as 
the underlying cause of death at the National Institutes of 
Health (NIH) Clinical Center between 1991 and 2007 were 
evaluated for the study. The reports included a complete 
clinical history and autopsy findings. Areas of metastatic 
spread were identified for each patient to reveal organs 
most frequently affected by metastases, and chemothera-
peutic treatment history and cause of death were compiled. 
A pathologist based the block selection on two criteria: the 
presence of at least one metastasis, and the presence of adja-
cent normal tissue for comparison. After histopathological 
review, ten cases were selected for the study.
Immunohistochemistry
Immunohistochemical staining of formalin-fixed and 
paraffin-embedded liver sections for CD31 expression was 
performed with a standard immunohistochemistry protocol 
using the Dako EnVision+ System-HRP kit (Dako North 
America, Inc, Carpinteria, CA). After deparaffinizing 
each 5 µm-thick histological section, antigen retrieval was 
performed using 1X citrate buffer with 0.05% Tween 20 
(Invitrogen Corporation, Carlsbad, CA) for 30 minutes in a 
steamer, then cooled slowly to room temperature.   Peroxidase 
block was applied for 30 minutes at room temperature. After 
rinsing with 1X phosphate buffered saline, tissue sections 
Magnet held on left,
pulls nanoparticles left
Applied magnetic force promotes transport of
particles from vessel reservoirs to each lesion
Then magnet on right,
pulls nanoparticles right
30 minutes 60 minutes
120 minutes 180 minutes
200 µm
N
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S
Figure 2 Schematic illustration of magnetic left-then-right shift option to increase nanoparticle levels into and throughout liver metastatic tumor foci. Left and right panels: 
appropriately chosen (strong and correctly sized) magnets can create sufficient magnetic gradients on therapeutic magnetic nanoparticles to displace them from dense 
distributions in normal tissue into adjacent poorly vascularized tumor regions. In this example, magnetic shift is shown in just two successive directions, but the process can 
be repeated in multiple spatial planes. Middle panel: computer simulations of the resulting therapeutic particle distributions in a 1 mm-wide tissue region using blood vessel 
geometry taken from autopsy data (gray markings). The color gradient shows the resulting nanoparticle concentration at each tissue location (red is high, white is low). 
Magnetic actuation increases nanoparticle concentration in the tumor area (marked by the black circle, also clearly visible by a lack of blood vessels) at 30, 60, 120, and 
180 minutes after systemic injection.
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were incubated overnight at 4°C with ready-to-use   anti-CD31 
primary mouse monoclonal antibody (Dako #IS610) and 
then incubated with mouse antimouse secondary anti-
body conjugated to peroxidase for 1 hour (Dako). The 
DAB + substrate-chromogen solution (Dako) was applied 
for 15 minutes; after rinsing in ddH2O, the samples were 
submerged in DAB Enhancer (Invitrogen) for 30 minutes. 
Sections were counterstained with hematoxylin, dehydrated, 
and coverslipped. Negative controls were established by 
replacing the primary antibody with antibody diluent, and 
no detectable staining was evident.
Image analysis (Aperio, ImagePro, Matlab)
After CD31 immunohistochemistry and hematoxylin coun-
terstaining, we acquired whole-section images with the 
Scanscope CS system (Aperio Technologies, Inc, Vista, CA) 
from the ten cases. Within each image, ten areas of normal 
and ten of tumor were chosen arbitrarily in 1.2 × 0.75 mm 
rectangles, totaling 200 images. We counted the number of 
nuclei (hematoxylin-stained; blue) and the number of blood 
vessels (CD31-positive cells; brown) using the Image-Pro 
system (Media Cybernetics) and Manual Color Selection. 
The appropriate colors for nuclei and vessels were chosen 
separately for each image to maximize the software’s rec-
ognition for each structure and to minimize background. 
For tumor images, Watershed was applied to separate the 
clustered nuclei. Matlab was used to compute and plot the dis-
tance from each tissue location to the nearest blood vessel.
Parameters for nanoparticle diffusion and 
magnetic transport through human tissue
At present, nanoparticle diffusivity and tissue resistance are 
not well known or characterized, especially within metastatic 
tumors in humans.19,20 However, there are several models that 
can be used to predict the relative movement of nanoparticles 
through tissue based on the size of the particles and relevant 
tissue parameters. Two traditional models (the Renkin Pore 
model19,20,24 and the Fiber-Matrix model19,20,25) were exam-
ined to determine the range of both diffusivity and tissue 
resistance.
The classical method of describing particle motion 
through different media is by a reduced diffusion coefficient 
that scales both the blood diffusion coefficient19,20,41 and 
the magnetic drift coefficient (by assuming Einstein’s 
relation).20,41 This reduced coefficient usually depends upon 
particle size (it decreases as the size increases) and the prop-
erties of the tissue (denser tissues increase particle motion 
resistance). Conversely, the magnetic force increases with 
particle size, it simply scales with particle volume.32,41,45 Thus, 
there is an optimal particle size for different tissue properties. 
The particles should be big enough so that the magnetic force 
is substantial but small enough to effectively move through 
the tissue (Figure 3).
Using Figure 3 and assuming a physiologically worst-case 
scenario for DMS of a very diffusive metastatic tumor (where 
the diffusion of nanoparticles is high, reducing the potential 
beneficial impact of the magnetic actuation, see Figure 1), 
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Figure 3 Optimal particle size for dynamic magnetic shift. Two classical models of tissues (Renkin Pore and Fiber-Matrix model) are used to determine the maximum velocity 
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There is a clear optimal particle size choice. For this tissue density it is 89 nm or 36 nm according to the Renkin or Fiber-Matrix model, respectively.
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a fiber concentration CF ≈ 0.3% using the Fiber-Matrix 
model19,20 was chosen, which led to an optimal particle 
diameter of 60 nm and a maximum particle magnetic drift 
velocity of ≈0.09 µm/s. The associated tissue diffusion 
coefficient, via the particle’s size and Einstein’s relation, is 
D ≈ 9 × 10–13 m2/s. These parameters were used to evaluate 
the DMS methodology.
Magnetic drug transport simulations 
(Comsol Multiphysics)
To examine the effect that low vascular density has upon 
magnetic targeting procedures, simulations were constructed 
using the histology of a representative small metastatic tumor 
(diameter ≈ 0.5 mm) and the surrounding normal liver paren-
chyma. Using finite element modeling software, the behavior 
of magnetic nanoparticles was examined with and without the 
application of magnetic actuation (Comsol Multiphysics).46 
All magnetic fields, gradients, resulting forces, and particle 
motions were computed from physical first principles,32,38,39,41,45 
using the most realistic available parameters for particle dif-
fusivity and resistance to motion in human tissue.19,20
The evolution of particle distributions in media was 
described by partial differential equations. Here, for diffu-
sion and magnetic transport in tissue, the appropriate partial 
differential equation with boundary and initial conditions 
is shown in Equations (1) and (2)47,48 (details provided in 
Supplementary information).
  ∂
∂
=−∇⋅ −∇ +



 

C
t
DC CV magnetic
Diffusion
DriftVelocity


  

 
  (1)
 C  (x,y,t)Vessels = C0 (x, y)e-λt, λ ≡ ln(2)/thalf-life  (2)
This type of formulation is standard, and the properties 
of tissue (D, 

Vmagnetic, thalf-life, C0) were chosen to match the 
properties of drug-coated 60 nm-diameter magnetic particles 
in human tissue.19,20,38,41,49 The decay constant, λ, defines how 
the particle concentration in blood is related to the nanocar-
rier half-life, thalf-life. A Fiber-Matrix model with a 1 nm-radius 
fiber volume concentration of CF = 0.3%19,20,25 was chosen to 
evaluate the worst-case situation for DMS where the diffusion 
coefficient of the particles is high, thus reducing the benefit 
of DMS (for this CF = 0.3%, the reduced diffusion coef-
ficient of the Fiber-Matrix model is DT ≈ 0.15).19,20,25,41 The 
magnetic field and magnetic gradient around a 20 × 40 cm 
magnet (2.5 T remnant magnetization) was solved using 
COMSOL,39,41 which gave the magnetic force at a depth 
of ≈11 cm in the body as Fmag ≈ 0.34 fN. Comparing this force 
with tissue resistance, Fresistance ≈ (1/DT) 6 π a η V magnetic, where 
a is the particle radius, η is the fluid viscosity, and Vmagnetic 
is the speed at which nanoparticles are transported through 
the region of tissue by the applied magnetic force, yielded a 
particle magnetic drift velocity of Vmagnetic
 ≈ 0.09 µm/s.38,41
Three treatment scenarios were considered: (a) no applied 
magnetic forces (for a treatment duration of t = 3 hours), (b) 
a constant unidirectional west magnetic force (t = 3 hours), 
and (c) a sequence of magnetic forces chosen by intuition that 
begins with no magnetic force (for t = 45 minutes) followed 
by a unidirectional east force (for t = 1.5 hours), which then 
switches to a unidirectional west force (for t = 45 minutes). 
Option c was chosen to test the effects of switching magnetic 
force directions on both the average and maximum-over-time 
nanoparticle concentration achieved in the tumor region to 
see whether it could be improved over the results of option b. 
Subsequently, we carried out a comprehensive search over 
magnetic force duration and number of pull directions (single 
or bidirectional pull) to go beyond option c and to find optimal 
DMS treatment parameters for a 1.5-hour treatment.
Results
Overall clinical picture
Autopsies from 18 women with metastatic breast cancer 
who died at the NIH Clinical Center were initially evaluated. 
The liver (89%) and the lungs (89%) were the extra-skeletal 
organs most commonly affected in this cohort of patients, 
although a majority of the women also had widespread 
systemic metastases. The most common causes of death 
were overall tumor burden and respiratory compromise, often 
associated with infections that were secondary to therapy 
and immune suppression. The chemotherapeutic treatment 
history in the patients varied; however, in all cases the drugs 
received were standard regimens. Grossly, the metastatic 
tumor foci appeared as firm, white nodules, in contrast to 
the adjacent, dusky, liver parenchyma (Figure 4).
Vessel measurements: normal  
liver and metastases
Ten autopsies were chosen for vessel analysis based on the 
quality of CD31 immunostaining. All ten patients had liver 
metastases, ranging from micrometastases that were only a few 
millimeters in diameter to grossly visible lesions that were a 
centimeter or more across. At the microscopic level the metas-
tases comprised sheets of irregularly shaped tumor cells with 
pleomorphic nuclei. Foci of chronic inflammation, necrosis, and 
microhemorrhage were variably observed in the tumors.
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Figure 4 Photograph of metastatic breast cancer in liver. The lesions appear grossly 
as firm, white nodules, consistent with a host desmoplastic response and poor 
vascularization. 
Notes: The image is representative of the pathological descriptions in the autopsy 
cases in the study but is not an actual image from one of the cases. Photo provided 
courtesy  of  Drs  Hanne  Jensen  and  Robert  D  Cardiff,  Center  for  Comparative 
Medicine, University of California, Davis.
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Figure 5 Photomicrographs of vessel staining in three cases of metastatic breast 
cancer in  liver.  Images on the left  are immunostained histological sections. On 
the  right  are  the  same  sections  visualized  in  black  and  white  to  highlight  the 
CD31-stained vasculature. Panels A–F are from normal liver and panels G–L are 
from matched tumors. At low power the normal sections show a fine meshwork 
of capillaries. In contrast, tumors exhibit vessels that are generally larger in size and 
fewer in number.
Normal liver in the patients contained a fine meshwork 
of small vessels and capillaries interspersed throughout the 
parenchyma, an architectural pattern consistent with an 
even distribution of blood flow and diffusion-based deliv-
ery of oxygen and nutrients to hepatocytes and associated 
support cells. In contrast, the tumor vessels were generally 
larger in diameter but fewer in number than in the adjacent 
normal liver, with a more random distribution and a greater 
vessel-to-vessel spatial separation. This difference in tumor 
vasculature is evident in the low-power histological views 
shown in Figure 5 and was observed in the metastases from 
nine of the ten patients analyzed.
To quantitatively assess the vasculature patterns of both 
normal tissue and tumor, 20 arbitrary histological regions 
were chosen for each case: ten that contained normal liver 
(green rectangles) and ten with tumor (red rectangles). As 
an example, a low-power microscopic view of one case 
and geographic regions selected for analysis is shown in 
Figure 6A. Overall, the measurements revealed that tumors 
contained fewer vessels and had more vascular   heterogeneity 
than normal tissue, consistent with the visual observations 
seen in Figure 5. Except for outlier case A98-28 (the only 
lobular breast cancer case in the series, see Discussion 
  section), all tumor cases had fewer vessels than normal tissue 
as measured using vessel count per cell number (Figure 6B) 
or using vessel count per area (Figure 6C).
We next assessed the tumor microenvironment in terms 
of regions with the lowest number of vessels. In other words, 
we purposefully looked for and measured subregions of 
tumors with the lowest vascular density, then compared 
these subregions against normal tissue of the same patient 
by computing the distance to the nearest blood vessel for 
every location within the tissue image. As seen in the panels 
across the top of Figure 7, in a normal region the average 
of the distance from each cell to its nearest blood vessel is 
5.3 ± 2.7 µm (the maximum is 67.8 µm; n ≈ 5500). In contrast, 
in the selected tumor region, the average was observed to be 
43.8 ± 6.9 µm (the maximum was 287 µm; n ≈ 5500). These 
results indicate that in addition to a lower average vascular 
density than normal tissue, there exist specific subregions 
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from its nearest blood vessel. In all examples, the tumor cases have cells located further away from nearest blood vessels (indicated by larger mean and maximum values).
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of tumors that are far away from all vessels, regions that 
are likely poorly perfused and difficult for systematically 
administered particles to access.
Magnetic drug transport simulations
To evaluate the utility of externally applied magnetic forces in 
equilibrating nanoparticle levels in tumors, a series of simula-
tions of Equations (1) and (2) were performed. The rate of 
nanoparticle extravasation through capillary walls, the decay 
constant λ in Equation (2), was inferred from the measured 
half-life (thalf-life) of nanoparticles in patients in the clinical trials 
of Lubbe et al.50,51 (For additional details on the simulations 
and mathematics, see Supplementary information.)
Figure 8 and Table 1 compare the time-progressed 
behavior of the magnetic nanoparticles for the three treat-
ment scenarios. Figure 8(A) represents the change in particle 
concentration with no applied magnetic forces over 3 hours 
for a tissue sample that includes a small metastasis.   Locations 
with high vascular densities (normal tissue) produced 
regions with high particle concentrations, whereas regions 
with lower vascular densities (tumor) experienced lower 
concentrations. In Figure 8(B), a constant west magnetic 
force was applied for 3 hours. The increase in particle con-
centration in the tumor is especially evident at the end of the 
second hour (at 120 minutes). Single direction shift yielded a 
15.8% (compared with in blood) time-averaged nanoparticle 
>0.36
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0
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Figure 8 Time progression of nanoparticle concentration for the three treatments. The panels across the top were from a histological image of normal liver containing 
a small metastasis (marked by the circle). (A) Nanoparticle concentration with no magnetic forces and only diffusive effects. The tumor region had a low nanoparticle 
concentration even after 180 minutes. (B) Nanoparticle concentration with a constantly applied magnetic force to the left (west). The nanoparticles were displaced to the 
left, increasing the particle concentration in the tumor. (C) Nanoparticle concentration with an alternating magnetic force first to the right (east) and then to the left (west). 
Nanoparticles from surrounding normal tissue were effectively brought into the tumor region by dynamic magnetic shift.
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Table 1 Time-averaged and time-maximum particle concentrations in tumor versus surrounding normal tissue
Case Time averaged Time maximum
Normal Tumor T:N Fold increase Normal Tumor T:N Fold increase
a. Diffusion only 20.4% ± 3.7%   9.9% ± 4.5% 0.49 28.9% ± 4.3% 15.8% ± 5.2% 0.55
b. Left shift 19.6% ± 3.2% 15.8% ± 3.5% 0.81 1.65 27.4% ± 4.1% 27.4% ± 2.9% 1.00 1.81
c. Shift two directions 19.7% ± 2.8% 18.0% ± 2.6% 0.91 1.86 29.0% ± 3.3% 30.1% ± 2.4% 1.04 1.89
Notes: The time-averaged “normal” and “tumor” values for the three treatment cases were computed by taking the average concentration over time within each tissue 
region (normal or tumor). Likewise, the time-maximum “normal” and “tumor” values were computed by taking the maximum over time at each location and then spatially 
averaging that value across the normal and tumor regions, respectively. Time-averaged ratio T:N = tumor average/normal average, and the fold increase = T:N average 
(left magnet or shift two directions)/T:N average (diffusion only); likewise, the time-maximum ratio T:N = tumor max/normal max, and the fold increase = T:N max 
(left magnet or shift two directions)/T:N max (diffusion only). The standard deviations are shown next to each percentage to quantify the spatial variance around the time-
averaged or time-maximum region concentrations. T:N values close to unity correspond to effective therapy normalization between tumor and normal tissue; fold increases 
quantify the benefit of dynamic magnetic shift.
concentration in the tumor, instead of the prior 9.9% value 
(a 1.6-fold improvement), whereas time-averaged particle 
concentration in the normal tissue remained almost the same 
as for diffusion only (19.6% instead of 20.4%). Thus, mag-
netic shift in just one direction partially renormalized particle 
concentration from normal to tumor tissue. Figure 8(C) simu-
lated an alternating bidirectional magnetic treatment. This 
simulation began with no magnetic forces (for 45 minutes) 
then a unidirectional east magnetic force (for 1.5 hours), 
which then switched to a unidirectional west force (for 
45 minutes). Alternating the direction of magnetic forces 
more effectively normalized particle concentration between 
normal and tumor tissue as the time-averaged concentration 
of particles in the tumor was 18.0%, which is close to the 
19.7% concentration in normal tissue, a 1.99-fold improve-
ment compared with no magnetic actuation. The time-
averaged metric is appropriate for time-dependent therapies 
or phase-specific therapies52 like paclitaxel53 and topotecan,54 
where it is important to ensure that cancer cells experience a 
higher dosage of therapy over a long time window to continue 
treating them until they enter the correct phase of their cell 
cycle. For phase-nonspecific therapies or dose-dependent 
drugs52 like gemcitabine55 and carboplatin,56 it would suf-
fice to increase the dose in cancer cells for just a short time, 
because the drug efficacy is not dependent upon the cancer’s 
cell cycle phase. In this phase-nonspecific case, it is more 
appropriate to consider the time-maximum   concentration 
at each tissue location. If such a time-maximum metric is 
considered, then even a single direction shift is sufficient to 
normalize the maximum-over-time nanoparticle concentra-
tion from normal to tumor regions (see Table 1).
Figure 9 plots the results from the simulations, showing 
the average and maximum nanoparticle concentration over 
time in the tissue for three scenarios: case (a) no applied 
0
0.15
>0.30
0
0.15
>0.30
Time
average
45 minute
half-life
Time
max
AB C
Figure 9 Visualization of the time-averaged (for slower-acting therapies) and time-maximum (for fast-acting therapies) concentration of therapy in normal and tumor tissue 
for the three cases from Figure 8. The top shows the time-averaged nanoparticle concentrations achieved across the tissue section over the 3-hour treatment window using: 
(A) diffusion only, (B) a left magnetic pull only, and (C) a two-directional magnetic pull. The tumor in the center of the image receives both significantly higher average and 
time-maximal nanoparticle levels when dynamic magnetic shift is applied.
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magnetic forces (diffusion only), case (b) west-only   magnetic 
force, and case (c) a sequence of alternating magnetic forces 
(east then west). In case (a), diffusion only with no mag-
netic forces applied, both the time-averaged and the time-
  maximum nanoparticle concentration in the tumor region 
was half what it was in the normal tissue (Ave[Normal]a = 20.4%, 
Ave[Tumor]a = 9.9%; Max[Normal]a = 28.9%, Max[Tumor]a = 15.8%) 
(Figure 6A). In case (b), a constant unidirectional (west) 
magnetic force improved the maximum nanoparticle 
concentration over time significantly in the tumor, but the 
average over time increased only moderately compared 
with the surrounding normal tissue (Ave[Normal]b = 19.6%, 
Ave[Tumor]b = 15.8%; Max[Normal]b = 27.4%, Max[Tumor]b = 27.4%) 
(Figure 6B). Finally, case (c), a bidirectional sequence of 
magnetic forces (east then west), was shown to be the most 
effective and improved both the average and maximum 
tumor nanoparticle concentrations relative to normal tissue 
(Ave[Normal]c = 19.7%, Ave[Tumor]c = 18.0%; Max[Normal]c = 29.0%, 
Max[Tumor]c = 30.1% in tumor) (Figure 6C). Overall, case (c) 
increased the Ave[Tumor] ratio for magnetic actuation versus 
diffusion by 1.86-fold, and increased the Max[Tumor] ratio by 
1.89-fold. In essence, magnetic shift was able to normalize 
the concentration of nanoparticles between normal and tumor 
cells, both according to the time-averaged (for slow-acting 
therapies) and time-maximum (for fast-acting therapies) 
metrics. (Further details on these simulations are provided 
in Supplementary information.)
The cases in Table 1 show that DMS can normalize 
nanoparticle concentrations across tumors by effectively 
transporting particles from well-vascularized normal tissue 
to poorly vascularized tumor regions. In the example in 
Table 1, the bidirectional mode timing was chosen based on 
intuition. It was thought beneficial to wait for some time to 
allow nanoparticles to first accumulate around vessels, and 
then to pull in the two different directions. To improve on 
case (c), based on the collected autopsy data, we sought to 
determine the best DMS parameters by optimizing the timing 
and direction of the applied magnetic force.
Timing optimization proceeded by defining a therapy 
normalization metric, by considering a cohort of tissue slices 
that included a metastatic tumor surrounded by normal tissue, 
and then by varying parameters and optimizing the metric 
to find the most effective DMS timing parameters. Because 
our goal was to normalize particle distribution across the 
tissue (we wanted to avoid the situation where nanoparticles 
are present in normal tissue but are absent from the tumors), 
the chosen metric had to include a notion of concentration 
uniformity. We also wanted to continue to consider both 
slow-acting and   fast-acting therapies, for which, respectively, 
time-averaged and time-maximum particle concentrations are 
more   appropriate. Thus, we chose to consider the following 
two metrics:
J
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(3)
The numerator was simply chosen to be the spatial aver-
age of the nanoparticle concentration across the entire tissue, 
for either the time averaged or time maximum. However, the 
denominator of the metrics penalizes high spatial variance 
across tissue. If the spatial variance is high (eg, the tumor 
has regions of both high and low particle concentration, an 
undesired situation because some tumor regions remain 
untreated), then the denominator is high and the metric is 
low. The numerator and denominator together try to ensure 
a nonzero and uniform concentration of therapy across the 
entire tissue, which is the normalization that DMS is trying 
to achieve. In particular, if DMS parameters can be chosen 
to create a completely uniform nanoparticle concentration, 
then this metric will reach infinity (its highest possible 
value). Without DMS, the therapy concentration is high in 
well-vascularized normal tissue but low in poorly perfused 
tumors (Figures 8A and 9A).
For DMS optimizations, we considered a small cohort 
of four tissue slices that included microtumors. Two DMS 
parameters were chosen: the duration of the first pull and 
the duration of the second pull. Because the treatment time 
was kept constant at 1.5 hours, this also defined the waiting 
period at the start by twait = 1.5 hours - tfirst-pull - tsecond-pull. Each 
of the two pull durations was varied across 25 values, for a 
total of 625 simulations per tissue slice and an overall total of 
2500 simulations. It took 4 days to complete the simulations 
on a Core i7 2.6 GHz computer running Windows 7 with 6 
GB of RAM. Figure 10 shows the fold increases in the two 
metrics J avg and J max versus the diffusion only case.
Figure 10 shows the four optimal situations as indicated 
by the blue diamonds. To increase the degree of normaliza-
tion for slow-acting therapies (time-averaged cases, Jtime-avg), 
it was best to allow the nanoparticles to diffuse a small 
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Figure 10 The degree of nanoparticle normalization fold increase over diffusion alone as a function of two dynamic magnetic shift parameters (pull left duration and pull right 
duration). For each tissue slice, the average over time for slow-acting therapies (left panel) or maximum over time for fast-acting therapies (right panel) was considered. Then, 
the degree of nanoparticle normalization, Jtime-avg and Jtime-max, was calculated using the formulae of Equation (3). The fold increase of the degree of normalization versus diffusion 
alone was plotted. High J values corresponded to high average concentrations and low spatial variances in the particle concentrations. Hence, the highest J value would be for 
a uniform high concentration. Low J values corresponded to low concentrations or high spatial variances that would correspond to hot and cold spots in the tissue and are the 
opposite of what dynamic magnetic shift is trying to achieve. The shift parameters are shown with the first pull duration and direction on the horizontal axis, and the second 
pull duration on the vertical axis. The first pull was either to the west (W) or east (E) for a fraction of the total time (hence, it is shown from -1 to 1). The second pull was 
always in the opposite direction to the first and was similarly a fraction of the total time. Thus, the location (+0.6, -0.2) corresponded to 20% (18 minutes) initial waiting time, 
followed by a 60% (54 minutes) pull to the east, then a final 20% (18 minutes) pull to the west. In this representation, pure diffusion (no pulling) corresponded to the vertical 
axis centered at “D” for diffusion only. For any pair where magnetic actuation was not applied for the full duration (anywhere within the interior of the triangles), diffusion 
occurs first during the initial waiting period. The optimal shift parameters are marked by the four blue stars. The found optima are different for phase-specific (time-averaged 
metric) and phase-nonspecific (time-maximum metric) therapies.
amount from the vessels and then shift in one direction 
for ≈40% of the time, and then shift in the opposite direction 
for the remainder of the time (≈60%). This corresponded 
to shifting in one direction until just before the half-life of 
the nanoparticle is reached (at time 0.5). Neglecting small 
statistical variations that remained because we analyzed 
only four tissue samples (due to computing constraints), 
it made no difference whether one shifts left or right first. 
In contrast, in order to increase the degree of normalization 
for fast-acting therapies (time-maximum cases, Jtime-max), it 
was best to shift the nanoparticles in only one direction – 
either only left or only right for the entire duration of the 
treatment. This ensured that every region of tissue sees as 
many new nanoparticles as possible. In this simulation, 
bringing the particles back in the opposite direction did not 
improve the maximum-over-time metric. Thus, depending 
on what kind of therapy was being considered (fast or slow 
acting), a different DMS strategy was optimal (single or 
bidirectional pull).
Discussion
Metastatic tumors exhibit a diverse set of cellular, patho-
logical, and structural features that make them a challeng-
ing target for therapeutic intervention.2,42 Evaluation at the 
microscopic level shows a variety of histopathologies, both 
within and among different cancer foci. For example, tumor 
grade, cellularity, degree of inflammation, desmoplastic 
host response, microhemorrhages, and necrosis can vary 
from lesion to lesion and even from subregion to subregion 
within a neoplasm. Moreover, the vascular characteristics 
of metastatic tumors differ from normal tissues and among 
cancer sites, both spatially and temporally.5 Tumor vessels 
are often dilated, saccular, tortuous, and disorganized in their 
patterns of interconnection, producing a geometric resistance 
to blood flow and a decrease in perfusion.7 The dysfunc-
tional vasculature is evident at the gross pathological level 
as a striking feature of metastatic lesions is their firm, white 
appearance, suggesting that blood perfusion is less than that 
of most normal organs (Figure 4).
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The chaotic nature of the vasculature and the subsequent 
increase in interstitial fluid pressure can result in uneven, 
fluctuating blood flow in tumors and prevent exposure to 
conventional nanotherapies that rely on the blood supply for 
diffusion-based distribution throughout the body, because the 
highest concentration of systemically delivered therapeutics 
is achieved at sites closest to the blood vessel, and the concen-
tration falls as the distance increases. As an example of this 
phenomenon, a study of local concentration of fluorouracil 
in liver metastases models as compared with adjacent nor-
mal tissue revealed limited fluorouracil penetration in areas 
of poor blood flow.4 Inadequate tumor perfusion can also 
result in hypoxia, which is postulated to be a central feature 
of cancer that is important to the physiological functioning 
and survival of the tumor cells and associated host cells. 
  Historically, hypovascular tumor foci have been indirectly 
observed by their resistance to ionizing radiotherapy that 
relies on tissue oxygen content at the time of treatment.6 More 
recently, hypoxic regions have been described to produce 
genomically unstable, clinically aggressive tumor cells that 
thrive in these regional microenvironments.9 Thus, poorly 
vascularized tumors or tumor subregions can be clinically 
problematic based on both the inability to achieve therapeuti-
cally effective drug levels and the hypoxic microenvironment 
that is favorable to tumor cell growth and progression.
In the present study, we found that metastatic breast 
tumors in liver consistently had a lower number of blood ves-
sels, on average, across the lesions than adjacent normal liver 
tissue (see Figure 6). Moreover, specific tumor subregions 
contained little or no vasculature, with vessel-to-tumor cell 
distances as large as 287 µm (see Figure 7). The one excep-
tion to this pattern was the outlier case A98-28.   Interestingly, 
A98-28 is a liver metastasis of lobular carcinoma, the only 
nonductal cancer that was included in the study. Detailed 
histopathological inspection of this tumor revealed large, 
poorly differentiated cells that did not grow in solid sheets but 
rather in clusters that invaded the liver through the   sinusoidal 
system, expanding it rather than replacing the normal tissue. 
The endothelium of the expanded sinusoids continues to 
express CD31; however, the majority of the CD31-positive 
cells are not blood vessels. Thus, although case A98-28 
appears well perfused, it may in fact be the least vascularized 
tumor in the series due to the pathological features associated 
with metastatic lobular carcinoma.
To date, magnetic drug delivery has been used for focus-
ing antineoplastic agents to primary, superficial tumors and 
has been evaluated in phase I clinical trials by placing a 
strong permanent magnet (0.8 Tesla) near the tumor.50,51,57 
Although this approach is promising to treat single   inoperable 
tumors in known, near-skin surface locations, it does not solve 
the larger clinical problem of increasing therapeutic levels 
in widespread metastatic disease, including lesions that are 
not near the skin surface. For nanotherapy, this is especially 
problematic because nanocarriers will diffuse substantially 
less effectively than small drug molecules. Simulations of 
the effect that magnetic gradients have upon nanoparticle 
movement in tissue revealed that it is possible to use DMS to 
transport nanoparticles from vessel reservoirs in normal tis-
sue to avascular tumor areas. Both single- and two-directional 
dynamic shifts were able to better distribute nanoparticles over 
the tissue space, with the bidirectional approach achieving a 
more even concentration throughout the tumor, showing the 
promise of using magnetic actuation for reaching into regions 
of the body that are inaccessible to pure diffusive movement of 
nanocarriers. Of particular note, the DMS method described 
and simulated here can be applied simultaneously to all 
metastatic foci in a given anatomical region of the body, as 
the magnets used would create sufficient gradients and forces 
on nanoparticles across all target locations, without the use of 
radiological imaging to identify lesions. This is important in 
breast cancer and other common epithelial tumors where many 
hundreds of metastatic sites typically exist in patients with 
advanced disease, ranging in size from grossly visible tumors 
to small, micrometastatic foci (for an example in liver, see 
Figure 4). A one-by-one approach to visualizing each tumor by 
radiological imaging and then using magnetic control to target 
them individually would be impractical; however, DMS does 
not require such imaging and can be applied simultaneously 
to all lesions within a defined anatomical zone.
DMS appears to be a promising solution to the problem 
of low blood supply in tumors. However, there are specific 
caveats that must be considered regarding this approach and 
the results described previously. First, we used vascular den-
sity as a surrogate marker of perfusion, and this assumption 
may not be accurate. In other words, the decrease in vessel 
number in metastatic lesions and the focal subregions with 
few or no vessels are consistent with decreased perfusion, but 
it is also possible that the unique nature of the tumor microen-
vironment, or other factors we have not yet considered, can 
compensate for the disordered vasculature, and so perhaps 
therapeutic levels of drugs or nanoparticles may reach most or 
all tumor cells by diffusion alone. Ultimately, measurement 
of actual drug levels in clinical cancer samples will be neces-
sary to gauge the effect of the abnormal tumor vasculature 
on drug concentration close to and distant from vessels, and 
such studies will be undertaken in future work.
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The second caveat is that the liver tissue utilized as a 
“normal control” in our study may not be an appropriate 
metric for evaluating tumor vessels. Liver is richly vas-
cularized with vessels and sinusoids in order to support 
the extensive metabolic functions of hepatocytes and has 
a high degree of vascular input and output. The fact that 
metastases have fewer vessels than adjacent liver tissue 
does not necessarily indicate that the tumor vasculature is 
incapable of providing therapeutic nanoparticle levels to 
cancer cells.
Finally, the use of external magnets as a nanoparticle 
delivery system requires particles of large enough size to 
generate sufficient force to displace them in tissue. The larger 
the particle, the larger the force. However, as the size of the 
particle increases, the diffusability (D in the differential 
equation described in the Results section) will decrease due 
to mechanical constraints in the microenvironment, includ-
ing physical barriers of cell-to-cell adhesion, the composi-
tion and density of stromal constituents, and the nature of 
the tumor cell-stromal interactions. Overall, the balance 
of magnetic force versus tissue resistance favors medium-
sized particles (.10 nm but ,200 nm). Magnetic forces 
increase with particle volume (radius cubed), whereas the 
tissue resistance initially increases slowly with particle size 
until the particle size nears a defining characteristic of the 
tissue (ie, pore radius for the Renkin Pore model), making 
the resistance grow exponentially thereafter.19,20 In normal 
highly organized and tightly compartmentalized tissues, the 
characteristics that define a tissue will favor smaller particles 
(ie, small pore radii ∼10 nm). But within the disorganized 
and haphazard structure of the tumor microenvironment, 
the tissues can be described to have much larger pore sizes 
that allow relatively unimpeded movement of even large-
sized nanoparticles (∼200 nm) through substantial areas of 
tumor space. Clearly, though, all of these critical aspects of 
magnetic drug delivery will need to be carefully evaluated 
both in future simulations and in model systems designed 
to test and optimize the method in the laboratory. The goal 
in this paper is to present the motivation and initial proof of 
concept for DMS based on autopsy studies of vasculature in 
human metastases and using mathematical modeling that has 
been validated against both in vitro and in vivo experiments 
in prior studies.41,58
Conclusion
In summary, DMS simulations based on quantitative 
analysis of the tumor vasculature in women who died of 
metastatic breast cancer indicate that improved nanoparticle 
  concentrations can be achieved using magnetic gradients 
generated by one or two externally held strong magnets. 
Depending on the desired therapy, slow or fast acting, we 
determined an optimal DMS strategy for improving the 
nanoparticle normalization throughout the entire tumor space 
within the treated anatomical region. The next steps of this 
effort are additional simulations to further refine the modeling 
followed by laboratory evaluation of DMS in ex vivo tissue 
specimens, in order to experimentally test and visualize nano-
particle transport in animals with poorly perfused tumors to 
mimic the situation observed in human patients.
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Supplementary information
Equation (1) describes the basic physics of nanoparticle trans-
port inside the body and shows that accumulation or depletion 
of particles at any location is due to transport by diffusion 
and applied magnetic forces. This type of formulation is 
standard.49,60 Parameters are chosen to reflect the tissue proper-
ties of the region of interest (eg, the diffusion coefficient can be 
changed to reflect parameters of normal or tumor tissue), and it 
is this equation that is simulated here. Equation (2) reflects our 
knowledge about the residence time of nanoparticles in vivo 
and states that the amount of particles that extravasate from 
blood to tissue at a given time is linked to the plasma concen-
tration, which decays exponentially over time due to uptake of 
the nanoparticles by the reticuloendothelial system.
Magnetic fields, gradients, and the 
resulting forces on nanoparticles
For any electromagnet or permanent magnet, a magnetic field 
surrounds the magnet with field lines leaving the north pole 
and re-entering the south pole.45 The field generated will be 
stronger closer to the magnet (specifically at the corners) and 
weaker as the distance from the magnet increases.40,41,45,61 The 
magnetic field falls off very quickly further from the magnet 
relative to its size (larger magnets will have a slower decreasing 
magnetic field strength),41,62 creating a magnetic field gradient, 
and it is this gradient that creates a force that attracts particles 
towards the magnet. For a 20 × 40 cm magnet with a remnant 
magnetization of 2.5 T, the field at 11 cm distance (along the 
long axis of the magnet) will be B ≈ 0.43 T or H ≈ 3.4 × 105 
A/m. The gradient of the magnetic field at that distance will be 
∂H/∂x ≈ 2.7 × 106 A/m2. Using these values and considering a 
magnetic nanoparticle with a diameter of 60 nm, the magnetic 
force41,45 acting on this particle will be FMagnetic ≈ (2/3)a3 µ0 
[χ/(1 + χ/3)] H (∂H/∂x) ≈ 0.34 fN = 0.34 × 10-15 Newtons (a 
femto-Newton is 10-15  Newtons). Considering a   Fiber-Matrix 
model with CF = 0.3%, as discussed in the Materials and 
methods section, the reduced diffusion coefficient of the 
described   Fiber-Matrix model will be DT ≈ 0.15. Assuming 
that the reduced diffusion coefficient impacts forced par-
ticle movement in a similar manner as diffusion (Einstein’s 
relation),19,20,42 the tissue resistance can be expressed as fol-
lows: Ftissue-resistance = (1/DT) 6 π a η VMagnetic. At equilibrium, the 
magnetic force and the tissue resistances are equal; therefore, 
the expected speed of a particle through a tissue space will be 
VMagnetic ≈ 0.09 µm/s or ≈90 nm/s.
Simulating nanoparticle movement
Each case simulated consisted of solving the constitutive 
Equation (1) over the entire image and marching it forward 
through time. Nanoparticles enter the surrounding tissue 
(shown in black in Figure 8, top row) from the identified 
blood vessels (white regions in Figure 8) over time. The 
amount of nanoparticles moving from the vessels into the 
adjacent tissue is described by Equation (2), from which 
Equation (1) generates the distribution of particles at the next 
time instant across the region of interest. This calculation is 
marched through time for 3 hours, creating a complete solu-
tion of the nanoparticle distribution for the entire treatment 
window (Supplemental Figure 1).
Boundary conditions
Two sets of boundary conditions are necessary to solve 
  Equation (1): one set to describe the extravasation from the 
blood vessels into the tissue (Equation (2)), and the second to 
describe the movement of nanoparticles out of the simulated 
region.
The first set of conditions is determined by the diffusion 
of particles from the vessels into the adjacent tissue governed 
by the nanoparticle concentration gradient (high in blood, 
low in tissue). Therefore, the movement of particles into the 
tissue is dependent upon the blood plasma concentration. 
Here we describe the concentration of nanoparticles within 
blood plasma as one that decays over time as described by 
  Equation (2). This decay models the known physiological 
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Figure S1 Simulation domain showing the larger region (left panel) that encompasses the smaller region of interest (right panel). The yellow ellipse represents the tumor.
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plasma   concentration of systemically injected nanoparticles. 
From this equation, the half-life (thalf-life) of nanoparticles in the 
blood plasma can be chosen to mimic physiological param-
eters in humans (here, thalf-life = 45 mins was used).50,51
The second set of boundary conditions defines the free 
movement, the flux, of nanoparticles out of the region of 
interest (Supplemental Figure 1). Nanoparticles leave only 
when the magnetic force pulls them out of the simulated 
region; therefore, the total flux of particles out of the tissue 
is equal to the convective flux created by the magnetic forces 
as described by the following equation:
 

   nD Ci · () -∇ =
Diffusionoutof thehistological region
there 0f fore
Convectivefluxfrommagneticforces To
 
  

nV CJ ii i ·() =
t talflux

Simulation region
In case (b) and (c) of Figure 8, nanoparticles are swept out 
of the simulated region then re-enter during treatment. We 
assessed the effects of particle re-entry on the accuracy of 
our simulation results by tripling the simulated region of 
Figure 8 to 3 × 1.8 mm, which centered on the original 
region of interest (Supplemental Figure 1). The increase 
in size was sufficient enough to accurately track all par-
ticles passing through the original region at any time. This 
did not change the results. In other words, all particles 
near the exterior boundary of the expanded region that 
would either enter or leave (ie, particles that would not 
be correctly tracked by our simulation) were too far away 
from the original region to contribute to its nanoparticle 
concentration.
Physiological modifications
The simulation framework presented can be modified, and 
detail can be added to address additional questions and to 
examine different treatment options. Variations in histology, 
changes to nanoparticles, and alterations in magnetic treat-
ment correspond to changing the parameters in Equation (1) 
and choosing their variation in time and space. For instance, 
the initial distribution of magnetic particles in blood vessels 
after systemic injection, but not yet in surrounding tissue by 
subsequent extravasation, diffusion, and magnetic forces, is 
reflected by choosing the initial condition C0 (x, y, z) to match 
the geometric distribution of blood vessels measured from 
the histology (Figure 5). Likewise, computing the magnetic 
forces and including the migration velocity they cause for 
nanoparticles in each location in the body, including the effect 
of varying magnetic fields during treatment, can be included 
in 

Vx yzt magnetic(,,,). The impact particle and physiological 
parameters have upon specific terms in Equation (1), however, 
is not always obvious. For example, varying the particle size 
will affect not only the diffusion coefficient D but also the 
magnitude of the particle migration velocity, 

Vmagnetic , as 
discussed in the Materials and methods section. The diffusion 
coefficient, as is described by Brownian motion, decreases as 
the particle size increases.49 The magnetic forces on particles 
scales with the volume of the particles but is opposed by the 
viscous resistance to nanoparticle motion offered by blood, 
interstitial fluid, or tissue, and that scales nominally with 
particle size. However, assuming various tissue models, as 
particle size increases above the geometrical thresholds of 
the tissue (ie, above the pore size in a Renkin model), the 
tissue resistance climbs very quickly.19,20,24 The net result 
is that the migration velocity increases with the square of 
particle diameter for an optimal range and then decreases 
dramatically.20,41,63–65 Variations in tissue properties also affect 
both the diffusion and the migration velocity parameters. 
Nanoparticles have more difficulty moving through dense 
cellular networks than through interstitial fluid;19,20 thus, 
tissue morphology effects both the diffusion and magnetic 
migration of the particles. Extravasation modifies how these 
particles move out from blood into surrounding tissue. In 
summary, although quantifying tissue properties of diffusion, 
migration, and extravasation is challenging and these param-
eters are often poorly known or uncertain, the mathematical 
model provides the ability to change them in simulations, to 
rapidly see the consequences, and to thus better understand 
how these tissue properties can affect nanoparticle distribu-
tion in tissue.
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